Drug Approval | May 07, 2026
Venus Remedies gets marketing authorization for Ceftriaxone in Argentina
Approval strengthens the company’s growing international anti-infective portfolio
Approval strengthens the company’s growing international anti-infective portfolio
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
This is an exciting and meaningful milestone for GRIN Therapeutics
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
Subscribe To Our Newsletter & Stay Updated
